# AbbVie: Phase 2 study in Extensive Stage-Small Cell Lung Cancer (ES-SCLC) (80 participants)

**Score:** 90/100

| Field | Value |
|---|---|
| Sponsor | AbbVie |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer |
| NCT ID | NCT07895043 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Extensive Stage-Small Cell Lung Cancer (ES-SCLC) |
| Intervention types | drug |
| Target enrollment | 80 |
| Posted | 2026-10-26 |
| Planned start | 2026-11-20 |
| Event | Newly registered study |
| Event date | 2026-10-26 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07895043). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.